Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
Anticancer Res. 2020 Jul;40(7):4087-4093. doi: 10.21873/anticanres.14407.
BACKGROUND/AIM: Hypertension is a risk factor for occurrence of renal cell carcinoma; however, it remains unclear whether hypertension affects development and prognosis of renal cell carcinoma. This study evaluated the impact of hypertension on the progression of renal cell carcinoma.
Renal cell carcinoma patients who were treated from October 2007 to December 2018 at our Institution were retrospectively analyzed.
Of 462 patients, the number of patients with and without hypertension was 234 (including 227 treated with anti-hypertensive agents) and 228, respectively. The tumor size was significantly smaller in the hypertension group than in the non-hypertension group (median 32 and 45 mm, respectively, p=0.010). The 5-year cancer-specific and metastasis-free survival in the hypertension group were significantly better than those in the non-hypertension group (93.6% and 80.4%, and 84.6% and 73.0%, respectively, p=0.021 and p=0.017). Propensity score matching revealed significantly better metastatic-free survival in the hypertension group than the non-hypertension group (p=0.022).
Renal cell carcinoma patients with hypertension show better prognosis with low metastasis possibility.
背景/目的：高血压是肾癌发生的一个危险因素；然而，高血压是否影响肾癌的发展和预后尚不清楚。本研究评估了高血压对肾癌进展的影响。
回顾性分析了 2007 年 10 月至 2018 年 12 月在我院治疗的肾癌患者。
在 462 名患者中，高血压组和非高血压组的患者数量分别为 234 名（包括 227 名接受抗高血压药物治疗的患者）和 228 名。高血压组的肿瘤大小明显小于非高血压组（中位数分别为 32 和 45mm，p=0.010）。高血压组的 5 年癌症特异性生存率和无转移生存率明显优于非高血压组（93.6%和 80.4%，84.6%和 73.0%，p=0.021 和 p=0.017）。倾向评分匹配显示，高血压组的无转移生存率明显优于非高血压组（p=0.022）。
患有高血压的肾癌患者具有更好的预后，转移的可能性较低。
